Patients with hemophilia A may need to switch between FVIII concentrates, either as a consequence of the availability of new factor concentrates, for instance from standard half-life (SHL) to an extended half-life (EHL) concentrate, or due to price agreements. This evidence concerns the gene F8 and hemophilia A.